targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000004468 | EFO_0000203 | NCT03236428 | Active, not recruiting | 2 | 2017-11-24 | null | null | null | null | Phase II+ | 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | 3 | LoF tolerant | Detected in many | Tissue enhanced | none | chembl | known_drug | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT03236428 | Active, not recruiting | 2 | 2017-11-24 | null | null | null | null | Phase II+ | 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | 3 | LoF tolerant | Detected in many | Tissue enhanced | none | europepmc | literature | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT03236428 | Active, not recruiting | 2 | 2017-11-24 | null | null | null | null | Phase II+ | 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | chembl | known_drug | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT03236428 | Active, not recruiting | 2 | 2017-11-24 | null | null | null | null | Phase II+ | 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | europepmc | literature | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT03236428 | Active, not recruiting | 2 | 2017-11-24 | null | null | null | null | Phase II+ | 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | chembl | known_drug | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT03236428 | Active, not recruiting | 2 | 2017-11-24 | null | null | null | null | Phase II+ | 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | europepmc | literature | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT04614558 | Recruiting | 2 | 2021-06-08 | null | null | null | null | Phase II+ | 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | 3 | LoF tolerant | Detected in many | Tissue enhanced | none | chembl | known_drug | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT04614558 | Recruiting | 2 | 2021-06-08 | null | null | null | null | Phase II+ | 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | 3 | LoF tolerant | Detected in many | Tissue enhanced | none | europepmc | literature | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT04614558 | Recruiting | 2 | 2021-06-08 | null | null | null | null | Phase II+ | 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | chembl | known_drug | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT04614558 | Recruiting | 2 | 2021-06-08 | null | null | null | null | Phase II+ | 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | europepmc | literature | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT04614558 | Recruiting | 2 | 2021-06-08 | null | null | null | null | Phase II+ | 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | chembl | known_drug | 413,311 |
ENSG00000004468 | EFO_0000203 | NCT04614558 | Recruiting | 2 | 2021-06-08 | null | null | null | null | Phase II+ | 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0005803 | hematologic disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | none | europepmc | literature | 413,311 |
ENSG00000004779 | EFO_1001249 | NCT00699036 | Unknown status | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 120,259,084,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | 2 | null | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000004779 | EFO_1001249 | NCT00699036 | Unknown status | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 120,259,084,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | null | null | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000004779 | EFO_1001249 | NCT00699036 | Unknown status | 2 | 2007-04-01 | null | null | null | null | Phase II+ | 120,259,084,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | null | null | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000004779 | EFO_1001249 | NCT04972396 | Recruiting | 1 | 2021-10-05 | null | null | null | null | null | 343,597,383,747 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | 2 | null | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000004779 | EFO_1001249 | NCT04972396 | Recruiting | 1 | 2021-10-05 | null | null | null | null | null | 343,597,383,747 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | null | null | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000004779 | EFO_1001249 | NCT04972396 | Recruiting | 1 | 2021-10-05 | null | null | null | null | null | 343,597,383,747 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0010282 | gastrointestinal disease | Other | null | null | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT02406066 | Completed | 1 | 2015-03-01 | null | null | null | null | null | 824,633,722,293 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | 2 | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT02406066 | Completed | 1 | 2015-03-01 | null | null | null | null | null | 824,633,722,293 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT02406066 | Completed | 1 | 2015-03-01 | null | null | null | null | null | 824,633,722,293 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00802412 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 893,353,198,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | 2 | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00802412 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 893,353,198,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00802412 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 893,353,198,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00208858 | Completed | 2 | 2004-12-01 | null | null | null | null | Phase II+ | 1,185,410,975,178 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | 2 | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00208858 | Completed | 2 | 2004-12-01 | null | null | null | null | Phase II+ | 1,185,410,975,178 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00208858 | Completed | 2 | 2004-12-01 | null | null | null | null | Phase II+ | 1,185,410,975,178 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT03813121 | Completed | 1 | 2019-06-01 | null | null | null | null | null | 1,365,799,601,280 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | 2 | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT03813121 | Completed | 1 | 2019-06-01 | null | null | null | null | null | 1,365,799,601,280 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT03813121 | Completed | 1 | 2019-06-01 | null | null | null | null | null | 1,365,799,601,280 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT01182766 | Active, not recruiting | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 1,374,389,536,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | 2 | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT01182766 | Active, not recruiting | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 1,374,389,536,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT01182766 | Active, not recruiting | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 1,374,389,536,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00755716 | Completed | 3 | 2006-04-01 | null | null | null | Phase III+ | Phase II+ | 1,382,979,470,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | 2 | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00755716 | Completed | 3 | 2006-04-01 | null | null | null | Phase III+ | Phase II+ | 1,382,979,470,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000011677 | EFO_0003768 | NCT00755716 | Completed | 3 | 2006-04-01 | null | null | null | Phase III+ | Phase II+ | 1,382,979,470,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000012779 | EFO_0002609 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,597,727,834,458 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | OTAR_0000006 | musculoskeletal or connective tissue disease | Other | 1 | LoF tolerant | Detected in many | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000012779 | EFO_0002609 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,597,727,834,458 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | OTAR_0000006 | musculoskeletal or connective tissue disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000012779 | EFO_0002609 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,597,727,834,458 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | OTAR_0000006 | musculoskeletal or connective tissue disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000012779 | EFO_0002609 | NCT00637780 | Terminated | 4 | 2010-06-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 618,475,292,173 | Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study | Phase 4 | 30/06/2010 | Terminated | 23/02/2017 | 31/01/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | OTAR_0000006 | musculoskeletal or connective tissue disease | Other | 1 | LoF tolerant | Detected in many | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000012779 | EFO_0002609 | NCT00637780 | Terminated | 4 | 2010-06-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 618,475,292,173 | Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study | Phase 4 | 30/06/2010 | Terminated | 23/02/2017 | 31/01/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | OTAR_0000006 | musculoskeletal or connective tissue disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000012779 | EFO_0002609 | NCT00637780 | Terminated | 4 | 2010-06-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 618,475,292,173 | Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study | Phase 4 | 30/06/2010 | Terminated | 23/02/2017 | 31/01/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | OTAR_0000006 | musculoskeletal or connective tissue disease | Other | null | LoF tolerant | Detected in many | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000014138 | EFO_1002001 | NCT01238211 | Active, not recruiting | 2 | 2010-12-14 | null | null | null | null | Phase II+ | 523,986,011,570 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | EFO_1002001 | NCT01238211 | Active, not recruiting | 2 | 2010-12-14 | null | null | null | null | Phase II+ | 523,986,011,570 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | EFO_1002001 | NCT01238211 | Active, not recruiting | 2 | 2010-12-14 | null | null | null | null | Phase II+ | 523,986,011,570 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00003204 | Completed | 3 | 1998-03-01 | null | null | null | Phase III+ | Phase II+ | 292,057,776,621 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00003204 | Completed | 3 | 1998-03-01 | null | null | null | Phase III+ | Phase II+ | 292,057,776,621 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00003204 | Completed | 3 | 1998-03-01 | null | null | null | Phase III+ | Phase II+ | 292,057,776,621 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00510887 | Terminated | 2 | 2007-01-01 | Terminated | stopped | null | null | Phase II+ | 352,187,319,161 | Low accrual. | Phase 2 | 31/01/2007 | Terminated | 12/05/2014 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00510887 | Terminated | 2 | 2007-01-01 | Terminated | stopped | null | null | Phase II+ | 352,187,319,161 | Low accrual. | Phase 2 | 31/01/2007 | Terminated | 12/05/2014 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00510887 | Terminated | 2 | 2007-01-01 | Terminated | stopped | null | null | Phase II+ | 352,187,319,161 | Low accrual. | Phase 2 | 31/01/2007 | Terminated | 12/05/2014 | 30/09/2013 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT02348216 | Active, not recruiting | 1 | 2015-04-21 | null | null | null | null | null | 377,957,122,485 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT02348216 | Active, not recruiting | 1 | 2015-04-21 | null | null | null | null | null | 377,957,122,485 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT02348216 | Active, not recruiting | 1 | 2015-04-21 | null | null | null | null | null | 377,957,122,485 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00169208 | Completed | 2 | 2001-04-01 | null | null | null | null | Phase II+ | 609,885,357,182 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00169208 | Completed | 2 | 2001-04-01 | null | null | null | null | Phase II+ | 609,885,357,182 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00169208 | Completed | 2 | 2001-04-01 | null | null | null | null | Phase II+ | 609,885,357,182 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00924326 | Completed | 1 | 2009-02-17 | null | null | null | null | null | 755,914,245,467 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00924326 | Completed | 1 | 2009-02-17 | null | null | null | null | null | 755,914,245,467 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00924326 | Completed | 1 | 2009-02-17 | null | null | null | null | null | 755,914,245,467 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01321541 | Completed | 3 | 2011-04-20 | null | null | null | Phase III+ | Phase II+ | 876,173,329,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01321541 | Completed | 3 | 2011-04-20 | null | null | null | Phase III+ | Phase II+ | 876,173,329,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01321541 | Completed | 3 | 2011-04-20 | null | null | null | Phase III+ | Phase II+ | 876,173,329,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT02295722 | Unknown status | 1 | 2015-04-01 | null | null | null | null | null | 42,949,674,404 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT02295722 | Unknown status | 1 | 2015-04-01 | null | null | null | null | null | 42,949,674,404 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT02295722 | Unknown status | 1 | 2015-04-01 | null | null | null | null | null | 42,949,674,404 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00110071 | Completed | 1 | 2005-01-01 | null | null | null | null | null | 77,309,411,723 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00110071 | Completed | 1 | 2005-01-01 | null | null | null | null | null | 77,309,411,723 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00110071 | Completed | 1 | 2005-01-01 | null | null | null | null | null | 77,309,411,723 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00119392 | Completed | 2 | 2004-06-01 | null | null | null | null | Phase II+ | 240,518,169,289 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00119392 | Completed | 2 | 2004-06-01 | null | null | null | null | Phase II+ | 240,518,169,289 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00119392 | Completed | 2 | 2004-06-01 | null | null | null | null | Phase II+ | 240,518,169,289 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01529827 | Completed | 2 | 2012-02-28 | null | null | null | null | Phase II+ | 317,827,580,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01529827 | Completed | 2 | 2012-02-28 | null | null | null | null | Phase II+ | 317,827,580,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01529827 | Completed | 2 | 2012-02-28 | null | null | null | null | Phase II+ | 317,827,580,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00562965 | Terminated | 3 | 2007-11-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 369,367,188,591 | See termination reason in detailed description. | Phase 3 | 30/11/2007 | Terminated | 09/01/2018 | 30/04/2011 | No_Context | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00562965 | Terminated | 3 | 2007-11-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 369,367,188,591 | See termination reason in detailed description. | Phase 3 | 30/11/2007 | Terminated | 09/01/2018 | 30/04/2011 | No_Context | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00562965 | Terminated | 3 | 2007-11-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 369,367,188,591 | See termination reason in detailed description. | Phase 3 | 30/11/2007 | Terminated | 09/01/2018 | 30/04/2011 | No_Context | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00079443 | Terminated | 2 | 2004-01-01 | Terminated | stopped | null | null | Phase II+ | 412,316,861,764 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00079443 | Terminated | 2 | 2004-01-01 | Terminated | stopped | null | null | Phase II+ | 412,316,861,764 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00079443 | Terminated | 2 | 2004-01-01 | Terminated | stopped | null | null | Phase II+ | 412,316,861,764 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01303887 | Unknown status | 3 | 2009-10-01 | null | null | null | Phase III+ | Phase II+ | 601,295,421,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01303887 | Unknown status | 3 | 2009-10-01 | null | null | null | Phase III+ | Phase II+ | 601,295,421,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT01303887 | Unknown status | 3 | 2009-10-01 | null | null | null | Phase III+ | Phase II+ | 601,295,421,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00393107 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 953,482,741,355 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00393107 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 953,482,741,355 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00393107 | Completed | 2 | 2000-03-01 | null | null | null | null | Phase II+ | 953,482,741,355 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03019640 | Completed | 2 | 2017-10-10 | null | null | null | null | Phase II+ | 970,662,610,863 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03019640 | Completed | 2 | 2017-10-10 | null | null | null | null | Phase II+ | 970,662,610,863 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03019640 | Completed | 2 | 2017-10-10 | null | null | null | null | Phase II+ | 970,662,610,863 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00140569 | Completed | 3 | 1994-01-01 | null | null | null | Phase III+ | Phase II+ | 1,099,511,629,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00140569 | Completed | 3 | 1994-01-01 | null | null | null | Phase III+ | Phase II+ | 1,099,511,629,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00140569 | Completed | 3 | 1994-01-01 | null | null | null | Phase III+ | Phase II+ | 1,099,511,629,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03128359 | Active, not recruiting | 2 | 2017-05-30 | null | null | null | null | Phase II+ | 1,357,209,666,455 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03128359 | Active, not recruiting | 2 | 2017-05-30 | null | null | null | null | Phase II+ | 1,357,209,666,455 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03128359 | Active, not recruiting | 2 | 2017-05-30 | null | null | null | null | Phase II+ | 1,357,209,666,455 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00850499 | Terminated | 2 | 2009-09-01 | Terminated | stopped | null | null | Phase II+ | 1,425,929,143,471 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00850499 | Terminated | 2 | 2009-09-01 | Terminated | stopped | null | null | Phase II+ | 1,425,929,143,471 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT00850499 | Terminated | 2 | 2009-09-01 | Terminated | stopped | null | null | Phase II+ | 1,425,929,143,471 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03105336 | Active, not recruiting | 2 | 2017-06-20 | null | null | null | null | Phase II+ | 1,606,317,770,278 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
End of preview. Expand
in Dataset Viewer.
Clinical evidence
Dataset of clinical studies annotated with their predicted stop reason and genetic evidence when available. Referenced in https://doi.org/10.1101/2023.02.07.23285407
Generated with the 22.04 Open Targets Data with this script.
- Downloads last month
- 55